NEWPORT NEWS, Va., July 16 /PRNewswire/ -- Dilon Technologies, makers of a gamma imaging system optimized for early breast cancer detection, today announced a three-year agreement with Amerinet, a leading national group purchasing organization. Effective immediately, the relationship offers Amerinet's 26,000 acute and non-acute healthcare providers and their patients' access to the Dilon 6800 Gamma Camera, used in detecting and diagnosing very early stage breast cancers.
"Dilon Technologies is committed to enhancing the standard of healthcare in communities across the nation, said David Rom, National Accounts Director for Dilon. "This strategic partnership with Amerinet will help physicians with difficult-to-diagnose patients and continue to aid in the fight against breast cancer."
The Dilon 6800 performs a molecular breast imaging technique called Breast-Specific Gamma Imaging (BSGI), which can detect lesions independent of tissue density and discover very early stage cancers. BSGI serves as a complementary diagnostic adjunct procedure to mammography and ultrasound for difficult-to-diagnose patients. With BSGI, the patient receives a radioactive tracing agent that is absorbed by all the cells in the body. Cancerous cells in the breast, due to their increased rate of metabolic activity, absorb a greater amount of the tracing agent than normal healthy cells, and generally appear as "hot spots" on the BSGI image.
Amerinet strategically partners with healthcare providers to reduce costs and improve the delivery of quality care. Supported by a team of clinical, data and supply chain experts, Amerinet offers a suite of tools, programs and services including a comprehensive and competitive portfolio that delivers practical solutions to address members' specific needs. To learn more, visit http://www.amerinet-gpo.com.
About Dilon Technologies
Dilon Technologies is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform Breast-Specific Gamma Imaging (BSGI), a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Technologies please visit http://www.dilon.com.
CONTACT: Nancy F. Morter of Dilon Technologies, +1-757-269-4910, ext. 302,
cell, +1-757-589-3914, nfmorter@dilon.com
Web site: http://www.dilon.com/
http://www.amerinet-gpo.com/
